Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 14, 2019 22:47 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $116.30 | $151,187.53 |
DisclosureSEC source: 0001093557-19-000123 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,200 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $116.01 to $116.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 13, 2019 Filed May 14, 2019 22:47 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,600 | $115.54 | $531,466.52 |
DisclosureSEC source: 0001093557-19-000123 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,500 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $115.00 to $115.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,980 | $119.56 | $475,844.42 |
DisclosureSEC source: 0001093557-19-000097 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,100 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $119.08 to $119.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 900 | $118.28 | $106,448.04 |
DisclosureSEC source: 0001093557-19-000097 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,080 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.91 to $118.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,120 | $117.12 | $131,178.43 |
DisclosureSEC source: 0001093557-19-000097 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,980 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.67 to $117.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,478 | $142.79 | $1,067,800.07 |
DisclosureSEC source: 0001093557-19-000085 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,100 F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 12,334 | $142.79 | $1,761,198.99 |
DisclosureSEC source: 0001093557-19-000085 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,578 F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,754 | $142.79 | $964,418.52 |
DisclosureSEC source: 0001093557-19-000085 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,912 F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,200 | $143.57 | $315,843.44 |
DisclosureSEC source: 0001093557-19-000085 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,666 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $143.03 to $143.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,800 | $142.64 | $542,046.44 |
DisclosureSEC source: 0001093557-19-000085 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,866 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $142.03 to $143.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:47 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 35,829 | $0.00 | $35.83 |
DisclosureSEC source: 0001093557-19-000063 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,666 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 800 | $150.42 | $120,339.52 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $149.83 to $150.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,100 | $149.02 | $461,968.82 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,637 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $148.58 to $149.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,100 | $148.14 | $311,091.27 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,737 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.58 to $148.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 22:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,024 | $141.39 | $144,781.31 |
DisclosureSEC source: 0001093557-19-000009 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $141.30 to $141.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 22:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,976 | $140.91 | $701,148.75 |
DisclosureSEC source: 0001093557-19-000009 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,861 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.35 to $141.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,162 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · derivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,162 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,012 | $123.18 | $124,658.67 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $123.08 to $123.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,560 | $122.41 | $313,379.33 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,849 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $122.01 to $122.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,988 | $121.64 | $606,753.29 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,409 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.01 to $121.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,602 | $120.39 | $313,249.84 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,397 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.00 to $120.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 11,162 | $4.58 | $51,121.96 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,161 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · derivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,162 Underlying: Common Stock · 11,161 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,395 | $148.74 | $356,231.58 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $148.32 to $149.09. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,766 | $147.99 | $409,337.02 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,232 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $147.28 to $148.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,000 | $146.87 | $293,739.40 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,998 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $146.22 to $147.21. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,700 | $145.55 | $247,430.07 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,998 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $145.19 to $146.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $143.00 | $71,500.00 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,698 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,800 | $142.25 | $256,045.68 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,198 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $142.00 to $142.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 11,161 | $4.58 | $51,117.38 |
DisclosureSEC source: 0001093557-18-000238 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 23:48 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,161 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000215 · edgardoc.xml · derivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,323 Underlying: Common Stock · 11,161 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 23:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,354 | $125.45 | $546,201.46 |
DisclosureSEC source: 0001093557-18-000215 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.00 to $125.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 23:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,807 | $124.32 | $846,231.26 |
DisclosureSEC source: 0001093557-18-000215 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,191 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.00 to $124.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 23:48 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 11,161 | $4.58 | $51,117.38 |
DisclosureSEC source: 0001093557-18-000215 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,161 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · derivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,484 Underlying: Common Stock · 11,161 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,802 | $143.76 | $977,822.87 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,837 F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,532 | $143.76 | $1,082,764.17 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,639 F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,761 | $144.04 | $541,724.29 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,171 F2 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $143.78 to $144.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,900 | $143.35 | $845,791.55 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,932 F2 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $142.78 to $143.77. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,500 | $142.31 | $213,470.55 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,832 F2 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $141.77 to $142.72. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 11,161 | $4.58 | $51,117.38 |
DisclosureSEC source: 0001093557-18-000192 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,161 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000167 · edgardoc.xml · derivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,645 Underlying: Common Stock · 11,161 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,178 | $124.24 | $146,351.78 |
DisclosureSEC source: 0001093557-18-000167 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,171 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $124.06 to $124.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,535 | $123.65 | $684,381.72 |
DisclosureSEC source: 0001093557-18-000167 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,349 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $123.08 to $124.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,448 | $122.41 | $544,477.01 |
DisclosureSEC source: 0001093557-18-000167 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,884 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $122.06 to $122.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 11,161 | $4.58 | $51,117.38 |
DisclosureSEC source: 0001093557-18-000167 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,400 | $100.56 | $241,333.68 |
DisclosureSEC source: 0001093557-18-000145 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,171 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $100.50 to 100.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,600 | $99.92 | $759,418.60 |
DisclosureSEC source: 0001093557-18-000145 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,571 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $99.49 to $100.31. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,219 | $99.10 | $418,103.32 |
DisclosureSEC source: 0001093557-18-000145 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,171 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $98.38 to $99.35. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| May 09, 2018 Filed May 10, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,464 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001093557-18-000089 · edgardoc.xml · derivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,464 shares Expires 2018-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.